Galectin-3: A biochemical marker to detect paroxysmal atrial fibrillation?
Yusuf Selcoki, H. Ibrahim Aydin, M. Bora Demircelik, Beyhan Eryonucu, Tugrul H. Celik, Hilmi Demirin, Ahmet Isleyen, Ali Erayman, Aydin Kosus
article (Uluslararası, Hakemli) | Yazar(lar): Yusuf Selcoki, H. Ibrahim Aydin, M. Bora Demircelik, Beyhan Eryonucu, Tugrul H. Celik, Hilmi Demirin, Ahmet Isleyen, Ali Erayman, Aydin Kosus | Yıl: 2016 | Dergi/Kurum: CLINICAL AND INVESTIGATIVE MEDICINE | İndeks: WOS.SCI — Özet: Purpose: Atrial fibrillation (AF) is the mo
Purpose: Atrial fibrillation (AF) is the most common form of arrhythmia. AF leads to electrical remodelling and fibrosis of the atria; however, the mechanism(s) remain poorly understood. Galectin-3 is a potential mediator of cardiac fibrosis. The present study aimed to examine the relationship between serum galectin-3 levels and paroxysmal AF.
Methods: Forty-six patients with paroxysmal AF and preserved left ventricular systolic function, and 38 age-and gender-matched control subjects, were involved in the study. Serum galectin-3 levels were analyzed with an enzyme-linked immunosorbent assay (ELISA).
Results: Serum galectin-3 levels (median 1.38 ng/mL; 1.21 ng/mL-1.87 ng/mL; p < 0.001) were significantly elevated in patients with paroxysmal AF compared with the control. Left atrial diameter was significantly higher in patients with paroxysmal AF (41.2 +/- 3.0 mm vs. 39.6 +/- 3.3 mm). Left atrial diameter was found to be significantly correlated with serum galectin-3 levels in patients with paroxysmal AF (r= 0.378, p = 0.001).
Conclusion: Serum galectin-3 levels are significantly elevated and significantly correlated with left atrial diameter in patients with paroxysmal AF.